GSK Secured New Cancer Drug in Recent Deal
The pharmaceutical company acquired an oncology candidate from Chimagen Biosciences to expand its cancer portfolio.
Updated on Sept. 20, 2026 in Cancer
Live Poll
Would you feel comfortable investing in a company that previously paid massive fines for bribery?
GSK has entered a £550 million agreement to acquire an early-stage oncology drug from Chimagen Biosciences that utilizes T-cells to combat cancer. The move is intended to bolster the company's medicine pipeline as it prepares for future revenue declines linked to HIV drug patent losses.
Why it matters
Expanding its cancer portfolio allows GSK to diversify its offerings and offset anticipated financial gaps. By partnering with Chinese firms for drug discovery, the company is positioning itself to capture global market share in oncology therapeutics.
The new drug candidate targets multiple myeloma and is expected to enter phase one trials next year. Separately, the company is developing the drug Ris-Rez, which has demonstrated a 54 percent reduction in death risk compared to rival small cell lung cancer treatments.
The players
GSK
A British multinational pharmaceutical and biotechnology company that focuses on research and development of vaccines and specialty medicines.
Chimagen Biosciences
A biotechnology firm that develops novel therapeutics, including T-cell based cancer treatments.
Hansoh Pharmaceutical
A major Chinese pharmaceutical company that focuses on the research, development, and production of drugs for oncology and other medical fields.
Luke Miels
The head of GSK who assumed his leadership position in early 2026.
Mark Reilly
A former executive who served as the head of Chinese operations for GSK during the 2014 bribery scandal.
The details
GSK is leveraging partnerships with firms like Chimagen Biosciences and Hansoh Pharmaceutical to address shortfalls in its oncology medicine development. These collaborations grant GSK global rights outside of China, building on a strategy to modernize its research and development efforts under new leadership.
Timeline
In 2014, a Chinese court fined GSK £300 million for operating a bribery network.
Luke Miels assumed the role of head of GSK in January 2026.
GSK signed the acquisition deal with Chimagen Biosciences in September 2026.
Phase one clinical trials for the new oncology drug are scheduled for 2027.
The Big Picture
This acquisition marks a strategic evolution for GSK in China, moving from a period of legal instability following the 2014 Chinese bribery network investigation to a model of formal, collaborative drug research partnerships.
The development of T-cell based therapies for conditions like multiple myeloma could provide new, more effective treatment options for patients in the future. These partnerships aim to accelerate the timeline for bringing specialized oncology medicines to global markets.
The takeaway
Strategic licensing and acquisition deals allow major pharmaceutical firms to rapidly expand their medicine pipelines without starting from zero in early-stage research. This approach helps companies hedge against the inevitable loss of revenue as older, successful patents expire.
Further reading
Learn more about advancements in global Cancer research and pharmaceutical developments.
Source note: This article includes information reported by Mail Online.
Live Poll
Would you feel comfortable investing in a company that previously paid massive fines for bribery?
